Physician profile
Caleb Chen
NPI 1730187105
$7,915.48
in general payments reported to CMS, 2019-2025
33 companies · $1,895 in 2025
The $1,895 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $533 · 2021: $611 · 2022: $1,372 · 2023: $1,236 · 2024: $1,594 · 2025: $1,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,709 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,708.69 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,104.25 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $664.92 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $577.39 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $554.67 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals Lp | $498.22 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $439.47 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $393.70 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $388.02 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $361.39 | 2019-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $342.54 | 2019-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $329.42 | 2020-2025 | Veltassa |
| Travere Therapeutics, INC. | $316.66 | 2022-2025 | |
| Akebia Therapeutics INC | $293.89 | 2019-2024 | Auryxia, Vafseo |
| Ardelyx, INC. | $262.22 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $259.68 | 2023-2025 | Purified Cortrophin Gel |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $212.35 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $181.32 | 2023-2025 | Jardiance |
| Genzyme Corporation | $97.77 | 2019-2023 | |
| Novo Nordisk INC | $93.85 | 2024-2025 | Rybelsus, Ozempic |
| Scpharmaceuticals INC. | $76.17 | 2025 | |
| Mallinckrodt Enterprises LLC | $72.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $70.18 | 2022-2024 | Ultomiris |
| Amarin Pharma, INC. | $62.93 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $58.43 | 2025 | Empaveli |
| Cormedix INC. | $57.91 | 2024-2025 | Defencath, Defencath |
| Glaxosmithkline, LLC. | $31.68 | 2023 | Benlysta |
| Janssen Pharmaceuticals, INC | $23.55 | 2022 | |
| Renalytix Ai, INC. | $23.08 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $18.84 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.06 | 2019 | |
| Genentech USA, INC. | $16.99 | 2019 | |
| Shield Therapeutics INC | $13.94 | 2023 | Accrufer |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.